Rational combination of a MEK inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer

Anna Spreafico, John J. Tentler, Todd M. Pitts, Aik Choon Tan, Mark A. Gregory, John J. Arcaroli, Peter J. Klauck, Martine C. McManus, Ryan J. Hansen, Jihye Kim, Lindsey N. Micel, Heather M. Selby, Timothy P. Newton, Kelly L. McPhillips, Daniel L. Gustafson, James V. DeGregori, Wells A. Messersmith, Robert A. Winn, S. Gail Eckhardt

    Research output: Contribution to journalArticlepeer-review

    62 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Rational combination of a MEK inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer'. Together they form a unique fingerprint.

    Keyphrases

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science